null

SMILES: O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1

InChI Key:

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 387820   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Tyrosine-protein kinase JAK1 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
Boehringer Ingelheim Pharmaceuticals Inc.					Assay Description Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...				Bioorg Med Chem Lett 19: 773-7 (2009) BindingDB Entry DOI: 10.7270/Q2C53P5D
					More data for this Ligand-Target Pair
Non-receptor tyrosine-protein kinase TYK2 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	11.6	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK3 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	82.8	n/a	n/a	n/a	n/a	n/a	n/a
Boehringer Ingelheim Pharmaceuticals Inc.					Assay Description Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...				Bioorg Med Chem Lett 19: 773-7 (2009) BindingDB Entry DOI: 10.7270/Q2C53P5D
					More data for this Ligand-Target Pair
Non-receptor tyrosine-protein kinase TYK2 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11.6	n/a	n/a	n/a	n/a	n/a	n/a
Boehringer Ingelheim Pharmaceuticals Inc.					Assay Description Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...				Bioorg Med Chem Lett 19: 773-7 (2009) BindingDB Entry DOI: 10.7270/Q2C53P5D
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10487083 (2019) BindingDB Entry DOI: 10.7270/Q2SX6GM6
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 [532-1132] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.20	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10487083 (2019) BindingDB Entry DOI: 10.7270/Q2SX6GM6
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK3 [512-1124] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	82.8	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10487083 (2019) BindingDB Entry DOI: 10.7270/Q2SX6GM6
					More data for this Ligand-Target Pair
Non-receptor tyrosine-protein kinase TYK2 [580-1182] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB MMDB UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11.6	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10487083 (2019) BindingDB Entry DOI: 10.7270/Q2SX6GM6
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10981911 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 [532-1132] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.20	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10981911 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK3 [512-1124] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	82.8	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10981911 (2021)
					More data for this Ligand-Target Pair
Non-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A] (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11.6	n/a	n/a	n/a	n/a	n/a	n/a
Janssen Pharmaceutica NV US Patent					Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...				US Patent US10981911 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK1 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	0.200	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	6.20	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK3 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem		n/a	n/a	82.8	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM387820 (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) Show SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1 |r,wU:18.21,wD:15.17,(-5.21,-1.06,;-4.44,.27,;-2.9,.27,;-2.13,-1.06,;-2.75,-2.47,;-1.61,-3.5,;-1.61,-5.04,;-.27,-5.81,;1.06,-5.04,;2.52,-5.52,;3.43,-4.27,;2.52,-3.03,;1.06,-3.5,;-.27,-2.73,;-.59,-1.22,;.44,-.08,;1.94,-.4,;2.97,.74,;2.5,2.21,;3.53,3.35,;5.03,3.03,;6.54,2.72,;.99,2.53,;-.04,1.38,;-5.21,1.6,;-4.44,2.94,;-5.21,4.27,;-5.21,5.81,;-6.54,5.04,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.20	n/a	n/a	n/a	n/a	n/a	n/a
Boehringer Ingelheim Pharmaceuticals Inc.					Assay Description Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...				Bioorg Med Chem Lett 19: 773-7 (2009) BindingDB Entry DOI: 10.7270/Q2C53P5D
					More data for this Ligand-Target Pair